BR0114884A - Compostos calcilìticos - Google Patents

Compostos calcilìticos

Info

Publication number
BR0114884A
BR0114884A BR0114884-2A BR0114884A BR0114884A BR 0114884 A BR0114884 A BR 0114884A BR 0114884 A BR0114884 A BR 0114884A BR 0114884 A BR0114884 A BR 0114884A
Authority
BR
Brazil
Prior art keywords
compounds
calcally
calcylitic
calculating
phosphate esters
Prior art date
Application number
BR0114884-2A
Other languages
English (en)
Inventor
Pradip Bhatnagar
Joelle L Burgess
James F Callahan
Maria A Lago
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0114884A publication Critical patent/BR0114884A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin

Abstract

"COMPOSTOS CALCILìTICOS". Novos compostos fosfato ésteres e processo de uso dos mesmos como compostos calcilíticos são providos.
BR0114884-2A 2000-10-25 2001-10-25 Compostos calcilìticos BR0114884A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24300600P 2000-10-25 2000-10-25
PCT/US2001/046184 WO2002038106A2 (en) 2000-10-25 2001-10-25 Calcilytic compounds

Publications (1)

Publication Number Publication Date
BR0114884A true BR0114884A (pt) 2004-07-06

Family

ID=22916975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114884-2A BR0114884A (pt) 2000-10-25 2001-10-25 Compostos calcilìticos

Country Status (16)

Country Link
US (1) US20040009980A1 (pt)
EP (1) EP1404654A4 (pt)
JP (1) JP2004519428A (pt)
KR (1) KR20040007407A (pt)
CN (1) CN1520401A (pt)
AU (1) AU2002239489A1 (pt)
BR (1) BR0114884A (pt)
CA (1) CA2426730A1 (pt)
CZ (1) CZ20031144A3 (pt)
HU (1) HUP0301582A3 (pt)
IL (1) IL155522A0 (pt)
MX (1) MXPA03003688A (pt)
NO (1) NO20031837L (pt)
PL (1) PL365643A1 (pt)
WO (1) WO2002038106A2 (pt)
ZA (1) ZA200303082B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
SI1619180T1 (sl) 2003-04-23 2010-04-30 Japan Tobacco Inc Antagonist CaSR
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
CN1856321B (zh) 2003-07-23 2012-10-03 诺瓦提斯公司 降钙素在骨关节炎中的用途
CA2645018A1 (en) 2006-03-08 2007-09-13 Takeda Pharmaceutical Company Limited Pharmaceutical combination
KR101129868B1 (ko) * 2006-10-04 2012-04-12 화이자 프로덕츠 인코포레이티드 칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체
KR101479371B1 (ko) 2008-06-05 2015-01-05 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물 및 그 용도
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336261A (en) * 1978-06-27 1982-06-22 Merck & Co., Inc. Aryloxypropanolamines
DK267779A (da) * 1978-06-27 1979-12-28 Merck & Co Inc Fr&mgangsmaade til fremstilling af n-aralkylamino-propoxycyanopyridiner
FR2543952B1 (fr) * 1982-09-03 1986-02-21 Bristol Myers Co Composes hydrocarbones heterocycliques appartenant aux series indoliques et leur application pharmacologique
DE3301198A1 (de) * 1983-01-15 1984-07-19 Hoechst Ag, 6230 Frankfurt N-arylalkylamin-3-propoxypyridin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
US4517188A (en) * 1983-05-09 1985-05-14 Mead Johnson & Company 1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols
WO2001035947A2 (en) * 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines

Also Published As

Publication number Publication date
PL365643A1 (en) 2005-01-10
EP1404654A2 (en) 2004-04-07
IL155522A0 (en) 2003-11-23
HUP0301582A3 (en) 2006-04-28
KR20040007407A (ko) 2004-01-24
NO20031837L (no) 2003-06-20
CA2426730A1 (en) 2002-05-16
US20040009980A1 (en) 2004-01-15
JP2004519428A (ja) 2004-07-02
AU2002239489A1 (en) 2002-05-21
HUP0301582A2 (hu) 2003-10-28
EP1404654A4 (en) 2008-12-03
NO20031837D0 (no) 2003-04-24
MXPA03003688A (es) 2003-08-07
CN1520401A (zh) 2004-08-11
CZ20031144A3 (cs) 2004-08-18
WO2002038106A3 (en) 2004-01-29
WO2002038106A2 (en) 2002-05-16
ZA200303082B (en) 2004-04-28

Similar Documents

Publication Publication Date Title
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
DE60010098D1 (de) 28-epirapaloge
DK1143967T3 (da) Anticonvulsive derivater egnede til behandling af Hortons hovedpine
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
ATE271058T1 (de) Mycophenol bisphosponatverbindungen
ATE263157T1 (de) Nematizide trifluorbutene
BR0010220A (pt) Compostos de pirimidinona
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
BRPI0414799A (pt) bifenilóxi-ácidos
ES2146774T3 (es) Polimeros de ioneno que contienen aniones biologicamente activos.
HN1996000017A (es) Isotiazolonas
ATE211135T1 (de) Aminocyclohexylester und ihre anwendung
BR9808491A (pt) Compostos calcilìticos
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
BR0114884A (pt) Compostos calcilìticos
SE9801494D0 (sv) Novel use
PT983272E (pt) Nova classe de compostos fotoactivos derivados de benzoporfirina
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
DE60128640D1 (de) Verfahren zur Herstellung von optisch aktivem 4-Halo-3-Hydroxybutanoat
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
DE59900628D1 (de) Nachvernetzung von hydrogelen mittels borsäureestern
BR9710386B1 (pt) processo de preparação de um composto e processo de transformação do composto.
DE60043228D1 (de) Herstellungsverfahren von 2-cyanopyridinen

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]